Sensorium Therapeutics, a US-based biotechnology company, announced on Wednesday that it has named Sam Rasty, PhD as its new chief business officer.

Dr Rasty has most recently served as chief executive officer of Sequence Bio, president and chief executive officer of PlateletBio and board director of Oxford Biomedica. He has worked as chief operating officer at Homology Medicines. His earlier career covered various leadership roles at Shire plc, Endo Pharmaceuticals, and GlaxoSmithKline in various capacities including R&D, new product planning, commercial strategy, marketing and business development.

Alexandra Glucksmann, Ph.D., Sensorium chief executive officer, said, 'Sam's expertise will fuel our business development and commercial strategies as we continue to progress our lead programs towards the clinic. Having shepherded product development from discovery to commercialisation across pharma and biotech companies of all sizes, he brings deep understanding of the drivers of market dynamics, business development, partnership, and other core activities as we prepare to become a clinical-stage company in early 2025.'